Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11
Needham has reiterated its Buy rating for Annexon (ANNX.US) and maintained a target price of $11. This indicates continued confidence in the company's stock performance from the analyst firm.
Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell 2000 Value Benchmark
Annexon, Inc. (NasdaqGS: ANNX) has been removed from the Russell 2000 Value Benchmark. This news follows several recent re-benchmarking announcements, including its addition to the Russell 2500 Growth and Russell 2000 Growth Benchmarks, and also being dropped from the Russell Microcap Value Benchmark index for being added to the Russell Microcap Growth Benchmark. The company is a clinical-stage biopharmaceutical firm focused on developing novel therapies for neuroinflammatory diseases.
Annexon, Inc. Actuals & Estimates (NASDAQ:ANNX)
This article provides an overview of Annexon, Inc. (NASDAQ:ANNX) financial actuals and estimates, including its current stock price, market capitalization, and analyst forecasts. It also covers historical stock performance, earnings reports, and other key financial data. Investors can find details on future earnings dates, revenue, net income, and dividend policies for ANNX.
Annexon, Inc.'s (NASDAQ:ANNX) Profit Outlook
This article analyzes the profit outlook for Annexon, Inc. (NASDAQ:ANNX) based on analyst forecasts. It discusses how the company is expected to transition from its current loss-making status to profitability and the projected financial performance over the coming years according to these estimates.
Annexon, Inc.'s (NASDAQ:ANNX) Profit Outlook
This article analyzes Annexon, Inc.'s financial outlook, focusing on its path to profitability. It details the average earnings growth forecast by 8 analysts, suggesting the company could become profitable by 2026. Key considerations for investors include the expected rate of revenue growth which is faster than the industry average, cash burn, and shareholder dilution, all of which are critical factors in the company's financial health and future stock performance.
Annexon (ANNX) Jefferies Global Healthcare Conference 2026 Summary
This article summarizes Annexon's (ANNX) presentation at the Jefferies Global Healthcare Conference 2026, highlighting its strategic focus on pioneering C1q inhibition for neuroinflammatory diseases. Key points include late-stage development programs for Guillain-Barré syndrome (GBS) and geographic atrophy (GA) with strong efficacy signals, and upcoming major clinical catalysts in 2024 for GBS, GA, and ANX1502. The company's corporate strategy involves seeking non-dilutive funding while maintaining a wholly-owned platform.
Annexon (ANNX) AGM 2026 Summary
Annexon's 2026 AGM summarized highlights from the company's annual meeting on June 11, 2026. Key points included a financial performance review indicating a cash runway into Q2 2027 and updates to the board and executive committee, noting the retirement of Tom Wiggans. The summary also mentioned ongoing clinical milestones, particularly relating to regulatory approvals and significant data readouts for multiple therapies.
Annexon Inc (ANNX) Institutional Confidence
This article examines the institutional confidence in Annexon Inc (ANNX) by detailing the shareholdings and activity of several major institutional investors. It highlights significant changes in holdings by firms like Redmile Group, Alerce Investment Management, and Adage Capital Management, indicating varying degrees of increased and decreased investment. The data provides insights into how large financial institutions are positioned with respect to Annexon Inc.
Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Annexon Inc (ANNX), including analyst ratings, target prices, and EPS estimates. Based on 11 analysts, the stock has a "Buy" trend with a target price of $14.50, representing an upside of over 220%. The report also includes past and future EPS expectations.
Annexon Inc (ANNX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Annexon Inc.'s (ANNX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports no data available for historical dividend payments or stock splits. The page primarily focuses on the company's current stock performance, market capitalization, and provides links to other financial analysis tools.
Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Annexon Inc (ANNX), covering its support, resistance, indicators, and moving averages. According to the analysis, relevant data for support and resistance have not been disclosed, while the technical indicators show mixed signals with 2 buy and 3 sell signals. The moving averages from MA5 to MA200 also present a mixed outlook with 3 buy and 3 sell signals, leading to an overall "Sell" signal based on moving averages and other technical indicators for today.
Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares
Annexon, Inc. EVP Ted Yednock exercised stock options to acquire 30,646 common shares at an exercise price of $1.8501 per share on June 11, 2026. This transaction increased his direct ownership to 184,807 shares. The options were fully vested and exercisable, representing a routine conversion of derivative awards.
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4)
Annexon, Inc. (ANNX) has announced inducement grants to new employees, adhering to Nasdaq Listing Rule 5635(C)(4). The report, provided by Refinitiv, is concise, indicating a brief notice regarding employee compensation. Further details would require signing in or creating a free account.
Two new Annexon hires receive options on 705,000 shares
Annexon (Nasdaq: ANNX) has granted stock options for 705,000 shares to two new non-executive employees under its 2022 Employment Inducement Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.64 per share, a ten-year term, and a four-year vesting schedule, aiming to attract and retain key talent. This move is consistent with Annexon's recent routine updates concerning employee inducement grants and conference participations.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced the grant of inducement equity awards to two new non-executive employees under the 2022 Employment Inducement Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards, approved on June 13, 2026, consist of options to purchase 705,000 shares of common stock at an exercise price of $4.64 per share. The options have a ten-year term and vest over four years, with a 25% initial vesting on the first anniversary of the grant date, followed by monthly vesting.
Annexon Stockholders Approve Directors, Compensation and Share Increase
Annexon, Inc. shareholders approved the election of Class III directors, advisory compensation for executive officers, and ratified KPMG LLP as auditors at their 2026 Annual Meeting. They also approved an amendment to increase authorized common shares from 300 million to 500 million to provide greater financial flexibility for the company. Despite these approvals, TipRanks' AI Analyst, Spark, rates ANNX as Neutral due to weak financial performance and accelerating cash burn.
Annexon (ANNX) director William Carson receives 65,000 stock options at $4.70
Annexon Inc. director William H. Carson was granted 65,000 stock options at an exercise price of $4.70 per share, which vest on the earlier of one year from June 11, 2026, or the next Annual Meeting, provided he continues his service as a director. These options expire on June 11, 2036. The transaction was a compensatory award, not an open-market purchase, and resulted in Carson holding derivative rights over 65,000 shares.
Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70
Annexon, Inc. director Bettina M. Cockroft was granted 65,000 stock options at an exercise price of $4.70 per share, expiring on June 11, 2036. These options will fully vest on the earlier of one year from June 11, 2026, or the next Annual Meeting, contingent on her continuous service as a director. This transaction is an award, not an open-market trade, and increases her derivative holdings to 65,000 stock options.
Annexon (NASDAQ: ANNX) director receives 65,000-share stock option grant
Annexon, Inc. director Muneer A. Satter was granted 65,000 stock options with an exercise price of $4.70 per share, expiring on June 11, 2036. The options will fully vest on the earlier of the first anniversary of June 11, 2026, or the next Annual Meeting, contingent on his continued board service. This grant is part of his equity compensation and was reported in a Form 4 filing.
Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70
Annexon, Inc. (ANNX) director Jung Choi was granted 65,000 stock options at an exercise price of $4.70 per share. These options will vest fully on the earlier of June 11, 2027, or the next Annual Meeting, provided Choi continues board service, and they are set to expire on June 11, 2036. Following this award, Choi directly holds stock options for 65,000 shares.
Annexon (ANNX) director William Waddill receives 65,000 stock options grant
Annexon, Inc. director William D. Waddill was granted 65,000 stock options with an exercise price of $4.70 per share. These options are part of his director compensation, will vest on the earlier of one year from June 11, 2026, or the next Annual Meeting, and expire on June 11, 2036. This transaction is considered a routine equity-based grant, not an open-market trade, and Waddill now holds a total of 65,000 such options.
[Form 4] Annexon, Inc. Insider Trading Activity
Annexon, Inc. director William A. Jones Jr. received a grant of 65,000 stock options with an exercise price of $4.70 per share, expiring on June 11, 2036. The options will vest fully on the earlier of June 11, 2027, or the next Annual Meeting, contingent on his continuous service. This transaction is classified as routine equity compensation rather than a market trade.
Annexon (NASDAQ: ANNX) reports 2026 annual meeting vote outcomes
Annexon, Inc. (NASDAQ: ANNX) announced the outcomes of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Shareholders elected two Class III directors, Bettina M. Cockroft, M.D. and Douglas Love, Esq., and approved several key proposals with substantial support. These proposals included the ratification of KPMG LLP as the independent registered public accounting firm, approval of executive compensation on an advisory basis, and an amendment to increase authorized common stock.
Annexon Inc Annual Shareholders Meeting Transcript
This article provides the transcript of the Annexon Inc 2026 Annual Shareholders Meeting. Douglas Love, President and CEO, opens the meeting and discusses forward-looking statements regarding the therapeutic and commercial potential of their product candidates. He highlights that these statements are based on current expectations, subject to risks detailed in SEC filings, and should not be considered representative of future views.
ANNX: All proposals passed as late-stage therapies advance and cash runway extends into 2027
Annexon, Inc. (ANNX) announced that all four shareholder proposals were approved at their 2026 AGM. The company is advancing late-stage therapies for neuroinflammatory diseases, including key milestones like regulatory submissions and pivotal data readouts. Annexon also confirmed a strong cash position that extends through 2027.
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
Annexon (NASDAQ: ANNX) is anticipating a "win season" with key clinical and regulatory milestones approaching, including Phase III data for its geographic atrophy drug, vonaprument, expected in Q4, and regulatory filings for its Guillain-Barré syndrome candidate, tanruprubart. The company emphasizes vision preservation for vonaprument and has demonstrated rapid patient benefit for tanruprubart, with a U.S. filing expected soon and a European decision in early 2027. Annexon also highlighted its $225 million cash reserve, which is projected to fund operations into the second half of 2027, covering these major catalysts.
ANNX: Three major clinical data readouts expected in 2024, each with strong differentiation
Annexon, Inc. (ANNX) anticipates three significant clinical data readouts in 2024 for its GBS, GA, and ANX1502 programs. These programs are highlighted for their strong differentiation and commercial potential, with the GA Phase III trial aiming to confirm vision preservation and the GBS program targeting a large, underserved market. This information is based on an AI-generated summary of the Jefferies Global Healthcare Conference 2026 Audio Transcript.
Annexon(ANNX.US) Director Buys US$3.32 Million in Common Stock
A director at Annexon (ANNX.US) recently purchased $3.32 million worth of the company's common stock. This significant insider transaction could be interpreted by investors as a signal of confidence in the company's future prospects.
Annexon director Muneer Satter buys $3.3m in common stock
Annexon director Muneer A. Satter recently purchased 613,497 shares of the company’s common stock for approximately $3.3 million, increasing his indirect holdings to over 10 million shares. This transaction follows a 146% return in ANNX shares over the past year and comes amidst varied analyst ratings, with Goldman Sachs initiating coverage as "Neutral," Jefferies reiterating "Buy," and H.C. Wainwright maintaining "Buy" with an increased price target. The company benefits from holding more cash than debt and positive revisions from some analysts.
Director-linked fund buys 613K Annexon (ANNX) shares in open market
Annexon, Inc. director Muneer A. Satter, through an affiliated investment entity called Alerce Medical Technology Partners, L.P., purchased 613,497 shares of ANNX common stock on May 28, 2026, at $5.41 per share. This open-market transaction increased the total Annexon shares associated with Satter to 10,342,134, though he disclaims beneficial ownership for many of these except to the extent of his pecuniary interest. This significant insider buying indicates a positive sentiment towards the company from a key director.
Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing
An insider at Annexon made a significant purchase of shares totaling $3,319,019, as disclosed in a recent SEC filing. The article also briefly mentions Unity Software's fourth-quarter financial results, noting a 35% revenue increase year-over-year to $609 million, exceeding estimates, despite a reported quarterly loss of 66 cents per share.
Annexon to Participate in Upcoming June Investor Conferences
Annexon, Inc. (Nasdaq: ANNX) announced that its President & CEO, Douglas Love, will participate in two upcoming investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts of these presentations will be available on the company's investor relations website. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon to Participate in Upcoming June Investor Conferences
Annexon, Inc. (Nasdaq: ANNX) announced that its president and CEO, Douglas Love, will participate in fireside chats at two upcoming June investor conferences: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. Live webcasts and replays of these presentations will be available on the company's website. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon to Participate in Upcoming June Investor Conferences
Annexon, Inc. (Nasdaq: ANNX) announced that its President & CEO, Douglas Love, will participate in two upcoming investor conferences in June: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company, which focuses on developing immunotherapies for neuroinflammatory diseases, will provide live webcasts and archived replays of these presentations on its investor relations website.
Annexon CEO Douglas Love to speak at Jefferies and Goldman Sachs in June
Annexon (Nasdaq: ANNX) announced that its President and CEO, Douglas Love, will participate in fireside chats at two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. The company will provide live webcasts and 30-day replays of these presentations on its investor website. This announcement is seen as a continuation of Annexon's active investor engagement, building on recent financial updates and their focus on targeted immunotherapies for neuroinflammatory diseases.
Annexon to Participate in Upcoming June Investor Conferences
Annexon, Inc. (Nasdaq: ANNX) announced that its president & CEO, Douglas Love, will participate in two upcoming June investor conferences: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts and replays of these presentations will be available on the company's investors page. Annexon is a biopharmaceutical company focused on advancing targeted immunotherapies for neuroinflammatory diseases.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. announced the granting of inducement equity awards to three new non-executive employees under its 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards consist of options to purchase 243,000 shares of common stock, with an exercise price of $5.21 per share, vesting over four years. This initiative aims to attract and retain talent for the biopharmaceutical company focused on neuroinflammatory diseases.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to three new non-executive employees under its 2022 Employment Inducement Award Plan, approved on May 11, 2026. These grants, totaling options to purchase 243,000 shares of common stock at an exercise price of $5.21, vest over four years subject to continued service. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent in the biopharmaceutical company focused on neuroinflammatory diseases.
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
This article analyzes Annexon's financial health and growth prospects. It examines the company's balance sheet, particularly its cash burn rate and cash runway, to assess its ability to fund future operations and development. The piece suggests that while Annexon's cash position appears strong for now, investors should monitor its financial resources closely.
Annexon (ANNX) insiders/affiliates report 8.7M-share stake (5.4%)
BVF entities and affiliates have reported a significant aggregate beneficial ownership of 8,698,173 shares in Annexon, Inc. (ANNX), representing approximately 5.4% of the company's outstanding shares. This disclosure, made via an amended Schedule 13G/A filing, details individual holdings for BVF (4,644,823 shares), BVF2 (3,399,850 shares), and Trading Fund OS (522,906 shares) as of March 31, 2026. The percentages are calculated based on 160,474,333 shares outstanding plus an additional 2,027,384 shares issued from pre-funded warrants.
Annexon, Inc. - common stock (NQ: ANNX)
This article provides a collection of headline news and analyst ratings related to Annexon, Inc. (Nasdaq:ANNX) common stock, compiled primarily from Benzinga. It includes details on Q3 2022 earnings, analyst upgrades/downgrades, and news regarding clinical trial data and stocks hitting 52-week lows. The content spans from May 2023 back to early 2022, offering a historical overview of significant company and market events.
Director William Carson Acquires Additional Shares of Annexon In
Director William Carson purchased 8,000 shares of Annexon Inc (ANNX) on May 11, 2026, bringing his total holdings to 78,405 shares. This recent acquisition is part of a broader trend where Carson has bought 52,805 shares over the past year without any sales. On the day of the transaction, Annexon Inc shares were trading at $5.78, with a market capitalization of $892.941 million.
Director adds Annexon (ANNX) shares in Rule 10b5-1 plan purchase
Annexon, Inc. director William H. Carson purchased 8,000 shares of common stock at $5.78 per share in an open-market transaction. This acquisition increases his direct holdings to 78,405 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The transaction, detailed in a Form 4 SEC filing, indicates a planned rather than discretionary purchase.
ANNX: Late-stage neuroinflammatory therapies show strong efficacy, with global filings and robust pipeline
Annexon, Inc. (ANNX) is advancing differentiated complement pathway therapies for neuroinflammatory diseases, highlighting strong efficacy and safety in late-stage programs for geographic atrophy and Guillain-Barré syndrome. The company is pursuing commercial and regulatory strategies in the U.S. and Europe, alongside further development in small molecule candidates. This information is based on an audio transcript from the Bank of America Global Healthcare Conference 2026.
Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty
Goldman Sachs initiated coverage on Annexon Biosciences (NASDAQ:ANNX) with a Neutral rating and a $7.00 price target, citing uncertainty around the Phase 3 trial data for its geographic atrophy (GA) treatment, vonaprument. The firm highlighted that the Phase 3 data for vonaprument, expected in Q4, is a binary event focused on vision preservation, but questioned the likelihood of success given a lack of statistical significance in Phase 2. Despite this, Annexon is also advancing other programs, and other analysts like Jefferies and H.C. Wainwright maintain Buy ratings with higher price targets, emphasizing the company's potential in the complement inhibitor space.
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN)
Healthcare sector analysts have provided recent ratings for three companies. Amylyx Pharmaceuticals Inc (AMLX) received a "Strong Buy" consensus with a $24.57 average price target. Annexon Biosciences (ANNX) also has a "Strong Buy" consensus, with an average price target of $15.40, while AMN Healthcare Services (AMN) holds a "Moderate Buy" consensus, with an average price target of $23.50.
Annexon, Inc. Stock 12‑Month Price Target Raised to $14.38, Implies 160% Upside
The average 12-month price target for Annexon, Inc. (ANNX) stock has been raised from $14.12 to $14.38 by 8 analysts, suggesting a 160% potential upside based on the May 7 closing price. The consensus rating remains "Buy" from 10 analysts.
Annexon Inc expected to post a loss of 29 cents a share - Earnings Preview
Annexon Inc (ANNX) is expected to announce an earnings loss of 29 cents per share. This information comes from a Refinitiv earnings preview. The article is very short, offering this solitary financial projection.
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Annexon (ANNX.US). This indicates continued confidence from the analyst firm in the company's prospects.
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its first quarter 2026 financial results, highlighting significant progress across its neuroinflammatory disease portfolio and reaffirming its financial runway into the second half of 2027. Key upcoming milestones include pivotal Phase 3 data for vonaprument in Geographic Atrophy expected in Q4 2026, a BLA submission for tanruprubart in Guillain-Barré Syndrome in 2026, and proof-of-concept data for ANX1502 for autoimmune conditions in 2026. The company maintains a strong balance sheet with approximately $225 million in cash, cash equivalents, and short-term investments as of March 31, 2026.
